ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

Presentation Details Title: Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated ... Poster Section 52 Poster Board Number: 19 Catherine E. Gleason, Ranya Odeh, Frances Hamkins-Indik ...

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), Monday announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial evaluating azenosertib in Cyclin E1+ platinum ...

We are grateful to our patients and their families for participating in this trial, which has the potential to result in a treatment option for thousands of women diagnosed with Cyclin E1+ PROC.” ...

In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 5.52%, which has investors questioning if this is right time to buy.

Tiziana Life Sciences Ltd’s TLSA share price has surged by 12.58%, which has investors questioning if this is right time to sell.